title: Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists.
abstract: Overt similarities exist between the effects of systemic cannabinoid CB1 inverse agonists and dopamine (DA) antagonists on appetitive behavior. The present set of studies was undertaken to apply a fine-grained analysis of food-reinforced operant lever pressing in rats in order to compare the pattern of effects produced by administration of the CB1 inverse agonist AM 251 and those induced by the DA D1 antagonist SKF 83566, and the D2 antagonist raclopride. Three groups of rats were trained on a fixed-ratio 5 (FR5) schedule and administered these compounds over a range of doses expected to suppress responding. All three drugs produced a dose-related suppression of total lever pressing. In addition to main effects of dose, regression analyses were performed to determine which of several response timing- and rate-related variables correlated most strongly with overall responding in each group. It was found that total session time spent pausing from responding was significantly better at predicting responding in the AM 251 group, while both DA antagonists produced significantly stronger regression coefficients (versus AM 251) from fast responding measures. These results suggest that, while several similarities exist, CB1, D1, and D2 antagonists are not identical in their pattern of suppression of food-maintained lever pressing.
authors.affiliation: Department of Psychology, University of Connecticut, Storrs, CT 06269-1020, USA. pmclaughlin@edinboro.edu
authors.forename: P J
authors.initials: PJ
authors.lastname: McLaughlin
authors.forename: K M
authors.initials: KM
authors.lastname: Winston
authors.forename: L A
authors.initials: LA
authors.lastname: Swezey
authors.forename: V K
authors.initials: VK
authors.lastname: Vemuri
authors.forename: A
authors.initials: A
authors.lastname: Makriyannis
authors.forename: J D
authors.initials: JD
authors.lastname: Salamone
mesh_terms: D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects* / Q000502:physiology; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D054314:Drug Inverse Agonism; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D005502:Food; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000502:physiology; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology; D012055:Reinforcement Schedule
chemical_list: D002186:Cannabinoids; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D043884:Receptor, Cannabinoid, CB1; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2
references.citation: Behav Pharmacol. 2007 Nov;18(7):591-600
references.pmid: 17912043
references.citation: Brain Res. 1993 Nov 19;628(1-2):218-26
references.pmid: 8313150
references.citation: J Neurosci. 2008 Sep 3;28(36):9037-46
references.pmid: 18768698
references.citation: FEBS Lett. 1994 Aug 22;350(2-3):240-4
references.pmid: 8070571
references.citation: Neurosci Lett. 2007 Jun 4;419(3):231-5
references.pmid: 17462824
references.citation: Behav Pharmacol. 1994 Oct;5(6):615-622
references.pmid: 11224241
references.citation: Psychopharmacology (Berl). 2003 Feb;165(4):370-7
references.pmid: 12447606
references.citation: Eur J Pharmacol. 2003 Jun 27;471(3):185-93
references.pmid: 12826237
references.citation: Pharmacol Biochem Behav. 2000 Aug;66(4):803-9
references.pmid: 10973519
references.citation: J Exp Anal Behav. 1991 Sep;56(2):331-43
references.pmid: 1955820
references.citation: J Exp Anal Behav. 1974 Nov;22(3):553-60
references.pmid: 16811820
references.citation: Psychopharmacology (Berl). 2006 Jan;184(1):26-35
references.pmid: 16328376
references.citation: Life Sci. 1998;63(8):PL113-7
references.pmid: 9718088
references.citation: Physiol Behav. 2008 Jun 9;94(3):422-31
references.pmid: 18394662
references.citation: Psychopharmacology (Berl). 1997 Jul;132(1):104-6
references.pmid: 9272766
references.citation: Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
references.pmid: 2308954
references.citation: Neuroscience. 2002;109(3):451-60
references.pmid: 11823058
references.citation: Pharmacol Biochem Behav. 1993 Mar;44(3):605-10
references.pmid: 8451265
references.citation: Psychopharmacology (Berl). 1998 May;137(2):147-56
references.pmid: 9630001
references.citation: Neuroscience. 1990;39(1):17-24
references.pmid: 2128534
references.citation: Psychopharmacology (Berl). 2000 Sep;152(1):47-54
references.pmid: 11041315
references.citation: Brain Res. 1991 May 3;547(2):267-74
references.pmid: 1909204
references.citation: Psychopharmacology (Berl). 2009 Apr;203(3):475-87
references.pmid: 19015837
references.citation: Psychopharmacology (Berl). 1996 May;125(2):105-12
references.pmid: 8783383
references.citation: Br J Pharmacol. 2006 Jan;147(1):109-16
references.pmid: 16258524
references.citation: Pharmacol Biochem Behav. 2000 Oct;67(2):265-70
references.pmid: 11124390
references.citation: Psychopharmacology (Berl). 2005 Jul;180(2):286-93
references.pmid: 15948012
references.citation: Psychopharmacology (Berl). 2008 Mar;196(4):565-74
references.pmid: 18004546
references.citation: Eur J Neurosci. 2005 Mar;21(6):1749-57
references.pmid: 15845103
references.citation: Psychopharmacology (Berl). 2007 Apr;191(3):507-20
references.pmid: 17031711
references.citation: Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):373-82
references.pmid: 11509194
references.citation: Psychopharmacology (Berl). 2002 Mar;160(2):182-91
references.pmid: 11875636
references.citation: Behav Pharmacol. 2001 Dec;12(8):641-5
references.pmid: 11856902
references.citation: Behav Neurosci. 2006 Apr;120(2):488-92
references.pmid: 16719712
references.citation: Behav Pharmacol. 2005 Sep;16(5-6):381-8
references.pmid: 16148442
references.citation: Pharmacol Biochem Behav. 2005 May;81(1):78-88
references.pmid: 15894067
references.citation: Pharmacol Biochem Behav. 1995 Mar;50(3):437-43
references.pmid: 7617683
references.citation: Behav Brain Res. 2008 Nov 21;193(2):298-305
references.pmid: 18602425
references.citation: Psychopharmacology (Berl). 1998 Nov;140(1):81-90
references.pmid: 9862406
references.citation: Psychopharmacology (Berl). 2007 Apr;191(3):579-86
references.pmid: 17072593
references.citation: Psychopharmacology (Berl). 1998 May;137(1):61-6
references.pmid: 9631957
references.citation: Brain Res. 2003 Feb 7;962(1-2):169-79
references.pmid: 12543468
references.citation: Psychopharmacology (Berl). 2002 Apr;160(4):371-80
references.pmid: 11919664
references.citation: Psychopharmacology (Berl). 1991;104(4):515-21
references.pmid: 1780422
references.citation: Eur J Pharmacol. 1996 Jul 4;307(3):331-8
references.pmid: 8836622
references.citation: Science. 1997 Jun 27;276(5321):2048-50
references.pmid: 9197269
references.citation: Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
references.pmid: 1666911
references.citation: Behav Pharmacol. 2003 Dec;14(8):583-8
references.pmid: 14665975
references.citation: Pharmacol Biochem Behav. 2006 Mar;83(3):396-402
references.pmid: 16616951
references.citation: J Exp Anal Behav. 1969 Jul;12(4):605-8
references.pmid: 16811382